uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results

Core Insights - uniQure N.V. (NASDAQ:QURE) has been recognized as one of the 12 best-performing stocks over the last three months, with analysts raising price targets following positive trial results for its gene therapy AMT-130 [1][2] Group 1: Analyst Ratings and Price Targets - RBC Capital reiterated a Buy rating on uniQure N.V. and increased its price target from $55 to $65 [1] - H.C. Wainwright raised its price target from $70 to $110 while maintaining a Buy rating [2] Group 2: Clinical Trial Results - The company reported positive topline data from its Phase I/II study of AMT-130 for Huntington's disease, indicating that the therapy slowed disease progression [2][3] - The pivotal study met its primary endpoint, showing that a high dose of AMT-130 slowed the disease by 75% over 36 months, with the treatment being generally safe and well-tolerated [3] Group 3: Regulatory Designations and Future Plans - AMT-130 has received Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT) status from the FDA [3] - uniQure N.V. plans to submit a biologics license application (BLA) in the first quarter of 2026 and aims to launch the treatment in the US later that year [3]